Clinical Trials · global
Intravenous Cell Therapy Slows Upper-Limb Decline in Duchenne Muscular Dystrophy, Phase 3 Trial Meets Primary Endpoint
The HOPE-3 trial showed that quarterly deramiocel infusions reduced the extent of upper-limb function decline by 54% in patients with advanced disease and produced signals of improvement in cardiac measures; however, one year of data is not yet sufficient to answer questions about long-term benefits and risks.
Duchenne muscular dystrophy progressively robs patients of the ability to walk, raise their arms, and even breathe, while heart muscle damage also often shapes long-term prognosis. A Phase 3 trial now shows that deramiocel, an experimental cell therapy delivered through the bloodstream, may slow the loss of upper-limb function at more advanced stages of the disease, offering a new therapeutic lead for patients whose mobility is already significantly limited.
HOPE-3 is a multicenter, randomized, double-blind, placebo-controlled trial that enrolled 106 patients with Duchenne muscular dystrophy who were either ambulatory or nonambulatory and had impaired skeletal muscle function. Participants received deramiocel or placebo once every three months over 12 months, for a total of four administrations; the study registration number is NCT05126758.
According to results announced by trial sponsor Capricor Therapeutics and published in The Lancet, the rate of decline in upper-limb function measured by the PUL 2.0 scale was reduced by 54% in the deramiocel group compared with the placebo group, meeting the primary endpoint, with a nominal p-value of 0.03. The scale assesses patients’ ability to perform everyday movements involving the shoulder, elbow, and hand, making it particularly relevant in practical terms for people who have lost the ability to walk.
The study also observed favorable changes in measures related to cardiac function and myocardial scarring. Duchenne muscular dystrophy damages not only skeletal muscle but also causes progressive cardiomyopathy; therefore, if these signals can be reproduced over a longer period and in a larger sample, the therapy’s value may extend beyond maintaining arm movement. However, the current data cannot establish that it prolongs survival, prevents major cardiac events, or preserves function permanently.
deramiocel is made from donated human heart tissue and is an allogeneic cardiosphere-derived cell therapy. Its design is not focused on replacing the patient’s defective gene, but on reducing harmful inflammation and muscle-tissue scarring through immunomodulatory and antifibrotic effects. This makes it a different strategy from gene therapies that directly target the dystrophin defect and, in theory, it may be suitable for a broader range of patients, but the trial has not completed this type of cross-therapy comparison.
Regarding safety, there were no deaths during the study, and serious adverse events were uncommon; however, 106 participants and a one-year blinded observation period remain insufficient to rule out infrequent or delayed risks. Trial registration data indicate that the study is currently ongoing but no longer recruiting, with a separate open-label extension expected to provide additional information on whether efficacy is sustained and on the long-term safety of repeated infusions.
deramiocel remained an unapproved experimental therapy when the results were published, and its biologics license application is under review by the U.S. Food and Drug Administration. Meeting the primary endpoint in a Phase 3 trial brings it one step closer to clinical use; the next key question will be how regulators weigh the magnitude of improvement on the functional scale, the maturity of the cardiac data, and the uncertainty left by the limited follow-up period.